Journal: Reproductive Biology and Endocrinology : RB&E

Article Title: Upregulated Talin1 synergistically boosts β-estradiol-induced proliferation and pro-angiogenesis of eutopic and ectopic endometrial stromal cells in adenomyosis

doi: 10.1186/s12958-021-00756-7

Figure Lengend Snippet: β-E 2 induced adenomyotic endometrial stromal cell proliferation in vitro. a . Cell proliferation rates of adenomyotic and normal endometrial stromal cells with or without β- E 2 . b . Numbers of formative colonies of adenomyotic and normal endometrial stromal cells with or without β- E 2 . c . and d . CCK-8 assay and colony formation assay were performed to evaluate the effects of β- E 2 on the proliferation of ADS eutopic and ectopic endometrial stromal cells. e . and f . Western blot and gray value analysis of molecular markers for cell division and proliferation including PCNA and Ki67 in ADS endometrial stromal cells treated with E 2 (10nM) or Fulvestrant (a selective estrogen receptor antagonist, 10 nM) or both or neither of them. GAPDH was used as a loading control. Data were presented as mean ± SD. NS no significance, * P < 0.05, ** P < 0.01. ADS_Eu_ESC, adenomyotic eutopic endometrial stromal cells; ADS_Ec_ESC, adenomyotic ectopic endometrial stromal cells

Article Snippet: Subsequently, cells were incubated in fresh medium (as control), β-E 2 (10nM, Sigma, USA), Fulvestrant (10 nM, ICI 182780, a selective ER antagonist, MedChem Express, USA) or β-E 2 plus Fulvestrant for 24 h.

Techniques: In Vitro, CCK-8 Assay, Colony Assay, Western Blot, Control

Journal: Reproductive Biology and Endocrinology : RB&E

Article Title: Upregulated Talin1 synergistically boosts β-estradiol-induced proliferation and pro-angiogenesis of eutopic and ectopic endometrial stromal cells in adenomyosis

doi: 10.1186/s12958-021-00756-7

Figure Lengend Snippet: β-E 2 induced adenomyotic endometrial stromal cell angiogenesis in vitro. a . b . Assessment of pro-angiogenetic ability of adenomyotic and normal endometrial stromal cells with or without β- E 2 . c . d . Tube and network formation assay of HUVEC cells treated with conditioned media (the whole cell filtrate from ADS_Eu_ESC and ADS_Ec_ESC added with either E 2 (10nM) or Fulvestrant (10 nM) or both. Images were captured when HUVEC were cultured with the conditioned media on Matrigel for 6 h. Branch points of capillaries were counted and analyzed. Scale bar = 100 μm. e . f . Western blot detection of angiogenesis-related proteins including VEGFB and ANGPTL4 in ADS_Eu_ESC and ADS_Ec_ESC cells after being treated with E 2 (10nM) or Fulvestrant (10 nM). GAPDH was used as a loading control. Data were presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001. HUVEC, human umbilical vein endothelial cells

Article Snippet: Subsequently, cells were incubated in fresh medium (as control), β-E 2 (10nM, Sigma, USA), Fulvestrant (10 nM, ICI 182780, a selective ER antagonist, MedChem Express, USA) or β-E 2 plus Fulvestrant for 24 h.

Techniques: In Vitro, Tube Formation Assay, Cell Culture, Western Blot, Control

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: Clonogenic survival assays indicate concentration-dependent radiosensitization of ER+ MCF-7 cells with tamoxifen ( a ) or fulvestrant ( b ). Radiosensitization was also observed in T47D cells with tamoxifen ( c ) or fulvestrant ( d ) treatment, but not in the ER-negative SUM-159 cells treated with tamoxifen ( e ) or fulvestrant ( f ). Clonogenic survival assays were performed in MCF-7 cells pretreated with CSS for 1 h compared to FBS-treated cells ( g ), or MCF-7 cells pretreated for 3 days with CSS before stimulation with β-estradiol ( h ). Clonogenic treatment times are displayed in a schematic ( i ). Data from three or four replicate experiments are graphed as mean ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; NS = not significant).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Concentration Assay

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: The neutral comet assay was used to assess dsDNA break repair in MCF-7 cells treated with ± 500 nΜ tamoxifen ± 25 nM fulvestrant ± 4 Gy RT ( a ). Representative images of comets are shown. NHEJ efficiency in MCF-7 cells was assessed using a transient pEYFP reporter construct. Cells were treated with tamoxifen ( b ) or fulvestrant ( c ) with AZD7762, a Chk1/2 inhibitor, used as a negative control and NU7441, a DNAPK inhibitor, used as a positive control. Data from triplicate experiments are graphed as mean ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Neutral Comet Assay, Construct, Negative Control, Positive Control

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: Immunofluorescence was used to stain Rad51 foci in MCF-7 cells treated with ±500 nM tamoxifen ± 4 Gy RT ( a ) and in T47D cells treated ± 2.0 μM tamoxifen ± 4 Gy RT ( b ). A stable homologous recombination reporter construct was used to assess HR efficiency in MCF-7 cells treated with tamoxifen ( c ). AZD7762, a Chk1/2 inhibitor, was used as a positive control; NU7441, a DNAPK inhibitor, was used as a negative control. Representative images of MCF-7 Rad51 foci at the 6 h timepoint are shown ( d ). Total Rad51 protein levels were assessed by western blot in MCF-7 and T47D cells treated ± tamoxifen ± RT at 6- and 16-h post-RT ( e ). Data from three or four replicate experiments are graphed as mean ± SD. (* P < 0.05; ** P < 0.01; NS = not significant).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Immunofluorescence, Staining, Homologous Recombination, Construct, Positive Control, Negative Control, Western Blot

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: MCF-7 cells were treated with 500 nM tamoxifen or 25 nM fulvestrant for one hour prior to 4 Gy radiation and stained for β-galactosidase at 14 days post-RT. Quantification of cells positive for β-galactosidase was performed for MCF-7 ( a ) and T47D ( c ) cells. Representative images of β-galactosidase staining are shown for each cell line ( b , d ). Data from three or four replicate experiments are graphed as mean ± SD. (* P < 0.05; ** P < 0.01; **** P < 0.0001).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Staining

Journal: NPJ Breast Cancer

Article Title: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

doi: 10.1038/s41523-022-00397-y

Figure Lengend Snippet: MCF-7 cells were injected into the mammary fat pads of CB17-SCID mice, and treatment was initiated when tumors were 80–100 mm 3 . Mice treated with the combination of tamoxifen and radiation received tamoxifen for 1 or 6 days prior to the start of radiotherapy ( a ). The average change in tumor volume was recorded for each treatment condition ( b ). Time to tumor doubling was assessed for each treatment ( c ). The combination treatment did not have significant toxicity as there were no changes in mouse weights ( d ). Tamoxifen with radiation was found to be synergistic using the fractional tumor volume method in which ratios >1 indicate synergy ( e , f ). Data are graphed as mean ± SEM. (** P < 0.01, *** P < 0.001, **** P < 0.0001).

Article Snippet: Tamoxifen was obtained from MedChemExpress (HY-13757A).

Techniques: Injection

Journal: Cell Reports Medicine

Article Title: CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer

doi: 10.1016/j.xcrm.2025.102053

Figure Lengend Snippet:

Article Snippet: Tamoxifen citrate , MedChemExpress , Cat# HY-13757.

Techniques: Recombinant, Red Blood Cell Lysis, Sequencing, Software, RNA sequencing